BiotechTube

VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Norovirus Infection

Conditions

Norovirus Infection

Trial Timeline

Mar 20, 2019 → Apr 1, 2021

NCT ID
NCT03897309

About VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets

VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets is a phase 1 stage product being developed by Vaxart for Norovirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03897309. Target conditions include Norovirus Infection.

What happened to similar drugs?

0 of 1 similar drugs in Norovirus Infection were approved

Approved (0) Terminated (0) Active (1)
🔄mRNA-1403ModernaPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07254728Phase 1Completed
NCT03897309Phase 1Completed

Competing Products

13 competing products in Norovirus Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
VXA-G1.1-NN + VXA-G2.4-NS + Placebo TabletsVaxartPhase 1
19
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19
VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-TVaxartPhase 1
23
VXA-G1.1-NNVaxartPhase 1/2
22
VXA-G1.1-NN Oral VaccineVaxartPhase 1
19
VXA-G1.1-NNVaxartPhase 1
19
Norwalk GI.1 VirusVaxartPhase 1
19
VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus InoculumVaxartPhase 1/2
22
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + PlaceboVaxartPhase 2
25
VXA-GI.1.NN + Placebo TabletVaxartPhase 1
19
CDI-988 + PlaceboCocrystal PharmaPhase 1/2
29